MAST
Phase 1 Terminated
66 enrolled
A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors
Phase 1 Terminated
250 enrolled
Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors
Phase 1/2 Terminated
8 enrolled 12 charts
Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors
Phase 1/2 Terminated
23 enrolled
An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies
Phase 1 Terminated
25 enrolled
A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
Phase 1 Terminated
10 enrolled
A Study of HMPL-306 in Advanced Solid Tumors With IDH Mutations
Phase 1 Terminated
42 enrolled
FIGHT-302
Phase 3 Terminated
167 enrolled
A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors
Phase 1 Terminated
94 enrolled 28 charts
HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors
Terminated
19 enrolled
STARBURST
Phase 2 Terminated
11 enrolled
FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)
Phase 1 Terminated
20 enrolled
SIRCCA
Phase 2/3 Terminated
89 enrolled 23 charts
A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations
Phase 1 Terminated
54 enrolled
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
Phase 2 Terminated
54 enrolled 11 charts
A Study of ABM-1310 in Patients With BRAF V600-Mutant Advanced Solid Tumors
Phase 1 Terminated
20 enrolled
Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors
Phase 1/2 Terminated
13 enrolled 24 charts
Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer
Phase 2 Terminated
17 enrolled
Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors
Phase 1 Terminated
53 enrolled
Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations
Phase 3 Terminated
48 enrolled 26 charts
EPIC
Phase 2 Terminated
4 enrolled 6 charts
Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC
Phase 2/3 Terminated
309 enrolled 17 charts
RELEASE
Phase 2 Terminated
41 enrolled 17 charts
ALpha-T
Phase 2 Terminated
1 enrolled 5 charts
Melphalan for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic Cholangiocarcinoma
Phase 2 Terminated
17 enrolled
Study of GNS561 in Patients With Liver Cancer
Phase 1/2 Terminated
50 enrolled
A Study of AbGn-107 in Patients With Gastric, Colorectal, Pancreatic or Biliary Cancer
Phase 1 Terminated
39 enrolled
Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.
Phase 1 Terminated
5 enrolled
Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma
Phase 1 Terminated
85 enrolled 17 charts
Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS)
Phase 3 Terminated
28 enrolled 24 charts
iNSITE2
Phase 2 Terminated
73 enrolled
XL119 Versus 5-Fluorouracil (5-FU) Plus Leucovorin (LV) in Subjects With Advanced Biliary Tumors
Phase 3 Terminated
248 enrolled